BioLineRx In-Licenses Novel Antisense Drug for the Treatment of Inflammatory Diseases.
Business Wire › September 08, 2006
Linked as:
Extract
BioLineRx In-Licenses Novel Antisense Drug for the Treatment of Inflammatory Diseases.
JERUSALEM -- BioLineRx, Ltd., Israel's leading drug development company, announced today that it has signed an exclusive worldwide license agreement with B.G. Negev (BGN) Technologies Ltd., the technology transfer company of Ben-Gurion University of the Negev, and Mor Research Applications, Lt...
See the full content of this document
Sponsored links
